Cargando…
Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir?
Autor principal: | Karlsson, Jan Olof G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796585/ https://www.ncbi.nlm.nih.gov/pubmed/31466917 http://dx.doi.org/10.1016/j.ebiom.2019.08.038 |
Ejemplares similares
-
Gastrointestinal AEs seen in the POP trial due to SOD mimetic activity of calmangafodipir? – Authors' reply
por: Dear, James W.
Publicado: (2019) -
Letter in response to: “Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose—the PP100-01 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial”
por: Karlsson, Jan Olof G., et al.
Publicado: (2019) -
May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?
por: Karlsson, Jan Olof G, et al.
Publicado: (2020) -
Superoxide Dismutases (SODs) and SOD Mimetics
por: Borgstahl, Gloria E. O., et al.
Publicado: (2018) -
Comment on “Calmangafodipir Reduces Sensory Alterations and Prevents Intraepidermal Nerve Fibers Loss in a Mouse Model of Oxaliplatin Induced Peripheral Neurotoxicity” Antioxidants 2020, 9, 594
por: Stehr, Jan Eric, et al.
Publicado: (2020)